Rothschild Investment Corp IL reduced its position in shares of Pfizer, Inc. (NYSE:PFE) by 3.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,031 shares of the biopharmaceutical company’s stock after selling 8,807 shares during the period. Pfizer makes up approximately 1.1% of Rothschild Investment Corp IL’s investment portfolio, making the stock its 21st biggest position. Rothschild Investment Corp IL’s holdings in Pfizer were worth $9,608,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Quadrature Capital Ltd grew its stake in shares of Pfizer by 1,566.2% in the fourth quarter. Quadrature Capital Ltd now owns 389,880 shares of the biopharmaceutical company’s stock worth $12,671,000 after purchasing an additional 366,480 shares during the last quarter. Ibex Wealth Advisors grew its stake in shares of Pfizer by 204.5% in the fourth quarter. Ibex Wealth Advisors now owns 88,097 shares of the biopharmaceutical company’s stock worth $2,799,000 after purchasing an additional 59,168 shares during the last quarter. Pekin Singer Strauss Asset Management IL grew its stake in shares of Pfizer by 2.8% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 85,723 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 2,345 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Pfizer by 0.5% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 717,407 shares of the biopharmaceutical company’s stock worth $23,301,000 after purchasing an additional 3,437 shares during the last quarter. Finally, Wealthfront Inc. boosted its position in Pfizer by 24.9% during the fourth quarter. Wealthfront Inc. now owns 97,703 shares of the biopharmaceutical company’s stock valued at $3,173,000 after acquiring an additional 19,498 shares during the last quarter. Institutional investors and hedge funds own 69.09% of the company’s stock.
Pfizer, Inc. (NYSE:PFE) opened at 35.36 on Friday. The stock has a market cap of $210.30 billion, a PE ratio of 25.87 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.84. The firm has a 50 day moving average of $33.64 and a 200-day moving average of $33.53.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. Pfizer’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. Equities analysts anticipate that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were paid a dividend of $0.32 per share. The ex-dividend date was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders have sold 464,521 shares of company stock worth $15,813,961 over the last quarter. Insiders own 0.06% of the company’s stock.
PFE has been the topic of a number of research analyst reports. Jefferies Group LLC set a $35.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Morgan Stanley restated a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a report on Monday, June 12th. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $37.72.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (NYSE:PFE) Shares Sold by Rothschild Investment Corp IL” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/09/17/rothschild-investment-corp-il-cuts-position-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.